Johnson & Johnson

News & Events zu Johnson & Johnson (JNJ)

$259.360

+5.680 (+2.19%)Zum Schluss

JNJ-News

JNJ-Events

10/20 08:00

Johnson & Johnson Launches Shockwave C2 Aero Coronary Catheter

Johnson & Johnson announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified coronary artery lesions in half the time as previous coronary IVL devices. Leveraging Shockwave IVL's differentiated mechanism of action, and building on improvements delivered in the Shockwave C2 Aero platform, this next-generation coronary IVL catheter delivers pulses at double the speed and decreases pause time between pulsing cycles by half, while maintaining the safety and effectiveness of prior-generation catheters.

10/19 08:30

Johnson & Johnson Reports One-Year Results for TREMFYA

Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or improved fistula remission through 48 weeks in adults with Crohn's disease, or CD. The findings build on the previously reported Week 24 results and further support the use of TREMFYA in one of the most difficult-to-treat manifestations of CD 2. The late-breaking findings are being presented at the 2026 United European Gastroenterology Week. Combined fistula remissiona, which incorporates both clinical and radiologic assessment, was maintained or improved in both TREMFYA maintenance regimens through Week 48. Among patients receiving TREMFYA 100 mg every 8 weeks (q8w), combined fistula remission further increased from 28% at Week 24 to 35% at Week 48. Similar findings were observed for rates of clinically assessed fistula remission. Results among patients receiving TREMFYA 200 mg every 4 weeks (q4w) remained consistent through Week 48. More than 90% of all randomized patients, which included both bio-naive and bio-experienced patients, completed treatment through Week 48. Safety findings through Week 48 were consistent with the well-established safety profile of TREMFYA in Crohn's disease. The 48-week findings reinforce the previously shared Week 24 results from FUZION, which showed that in the overall study population at Week 24, 28% of patients receiving TREMFYA 100 mg q8w and 27% receiving TREMFYA 200 mg q4w achieved combined fistula remission compared with 10% receiving placebo, making TREMFYA the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomized, placebo-controlled trial in patients with Crohn's disease with perianal fistula.

10/13 20:00

10-Year Treasury Yield Falls Below 5.2%, Financial Stocks Under Pressure

The yield on the 10-year Treasury note slipped below 5.2% for the first time in nearly two weeks on Tuesday, and yet sentiment in equities remained cautious, with little support from large financials ringing in the start of the Q3 earnings season.Energy was the best-performing sector in the S&P 500 as WTI crude oil gained for the fourth consecutive session, rising above $94 per barrel amid escalating conflict between Saudi Arabia and Yemeni Houthis.   Healthcare was the worst-performing sector in the benchmark index, dragged down by disappointing Q3 results out of Johnson & Johnson.   Financials were also under pressure, with shares of JPMorganending the day down nearly 1% after a rare earnings miss.  Citiand Wells Fargofared worse, dropping 5.6% and 3.1% on earnings.  In Tech, Semiconductor Equipment names were dragged down by a disappointing investor day presentation by Applied Materials, which shed 7% on the day, though Semiconductors - with the exception of more losses by Micron- largely held steady.In the opening hour of the evening session, S&P e-minis are a little changed while the Nasdaq 100 contract is down by 0.1%.   Precious metals are holding steady, though the U.S. Dollar has pared some of its recent gains ahead of Wednesday's key CPI data.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -AZZ Inc.up 1.8%ALSO HIGHER -Liquidiaup 46.1% after settlement agreement with United TherapeuticsGameStopup 2.2% after insider buyLOWER -Biomea Fusiondown 31.5% after announcing Phase 1 GLP-131 clinical trial results for BMF-650Tarsus Pharmaceuticalsdown 2.7% after registering stock for holdersBank of Americadown 2.1% after disclosing $1.2B fine from the Treasury Department due to money laundering allegations

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln